Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges
The DOI matches its Crossref record; 176 of the 177 references it cites were found in a registry or an index.
Abstract
In vivo gene replacement for the treatment of inherited disease is one of the most compelling concepts in modern medicine. Adeno-associated virus (AAV) vectors have been extensively used for this purpose and have shown therapeutic efficacy in a range of animal models. Successful translation to the clinic was initially slow, but long-term expression of donated genes at therapeutic levels has now been achieved in patients with inherited retinal disorders and haemophilia B. Recent exciting results have raised hopes for the treatment of many other diseases. As we discuss here, the prospects and challenges for AAV gene therapy are to a large extent dependent on the target tissue and the specific disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This immune cascade model might explain why re-administration in patients could become difficult, and why the administration of rAAVs in patients with high neutralizing antibodies (nAbs) are generally not included in clinical trials [327].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [327]
Citations
Cites
The Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205
LMO2 -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., et al. (2003) · Science · doi:10.1126/science.1088547 · Cited by 3,587
Genome editing with engineered zinc finger nucleases
Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S., & Gregory, P. D. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2842 · Cited by 2,285
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationSafety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
Maguire, A. M., Simonelli, F., Pierce, E. A., Pugh, E. N., Mingozzi, F., Bennicelli, J., Banfi, S., Marshall, K. A., Testa, F., Surace, E. M., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802315 · Cited by 2,145
Self-citationProphylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia
Manco-Johnson, M. J., Abshire, T. C., Shapiro, A. D., Riske, B., Hacker, M. R., Kilcoyne, R., Ingram, J. D., Manco-Johnson, M. L., Funk, S., Jacobson, L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067659 · Cited by 1,950 · cited 1×
“The disease is currently treated by intravenous infusion of clotting factor concentrate”
BackgroundEffect of gene therapy on visual function in Leber’s congenital amaurosis
Bainbridge, J. W. B., Smith, A. J., Barker, S. S., Robbie, S., Henderson, R., Balaggan, K., Viswanathan, A., Holder, G. E., Stockman, A., Tyler, N., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802268 · Cited by 1,924
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854
Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Research works printed but not linked: 3
- Basner-Tschakarjan, E. et al. Dose-dependent activation of capsid-specific T cells after AAV serotype 8 vector administration in a clinical study for hemophilia. Mol. Ther. (in the press).
- Mingozzi, F. et al. Modulation of T cell response to the AAV capsid in subjects undergoing intramuscular gene transfer for lipoprotein lipase deficiency. Hum. Gene Ther. 19, 1090 (2008).
- Muzyczka, N. & Berns, K. I. in Parvoviridae: The Viruses and their Replication (eds Knipe, D. M. & Howley, P. M.) 2437–2477 (Lippincott, Williams and Wilkins, Philadelphia, 2001).
Cited by
Items 501–600 of 892
Yang, J., Pattanayak, A., Song, M., Kou, J., Taguchi, H., Paul, S., Ponnazhagan, S., Lalonde, R., & Fukuchi, K.-I. (2012) · Journal of Molecular Neuroscience · doi:10.1007/s12031-012-9877-3 · Cited by 23
“It is possible to achieve long-term gene expression after a single administered dose of rAAV in many tissues including nondividing cells like neurons and muscles (McCown 2005; Mingozzi and High 2011).”
BackgroundAAV-delivered muscone-induced transgene system for treating chronic diseases in mice via inhalation
Wu, X., Yu, Y., Wang, M., Dai, D., Yin, J., Liu, W., Kong, D., Tang, S., Meng, M., Gao, T., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45383-z · Cited by 26
“In addition, the introduction of foreign proteins delivered by rAAVs into a mammalian organism may trigger adaptive or innate immune responses, potentially resulting in a reduction of transgene products 10,31 – 33 .”
Antibody Gene Therapy: Getting Closer to Clinical Application?
Guijarro-Muñoz, I., Compte, M., Álvarez‐Vallina, L., & Sanz, L. (2013) · Current Gene Therapy · doi:10.2174/15665232113139990025 · Cited by 21
Improved osteogenic vector for non-viral gene therapy
Hacobian, A., Posa-Markaryan, K., Sperger, S., Stainer, M., Hercher, D., Feichtinger, G. A., Schuh, C. M. A. P., & Redl, H. R. (2016) · European Cells and Materials · doi:10.22203/ecm.v031a13 · Cited by 20
Ionic liquids with thioether motifs as synthetic cationic lipids for gene delivery
Gaitor, J. C., Paul, L. M., Reardon, M. M., Hmissa, T., Minkowicz, S., Regner, M. J., Sheng, Y., Michael, S. F., Isern, S., & Mirjafari, A. (2017) · Chemical Communications · doi:10.1039/c7cc03235h · Cited by 19
Systemic gene delivery transduces the enteric nervous system of guinea pigs and cynomolgus macaques
Gombash, S. E., Cowley, C. J., Fitzgerald, J. A., Lepak, C. A., Neides, M. G., Hook, K., Todd, L. J., Wang, G., Mueller, C., Kaspar, B. K., et al. (2017) · Gene Therapy · doi:10.1038/gt.2017.72 · Cited by 20
“Viral vectors are commonly used in the central nervous system for basic and pre-clinical studies and have an excellent safety profile in clinical testing(4–6).”
Jiang, L., Wang, L., & Cheng, X. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.43372 · Cited by 26
Hoshino, Y., Nishide, K., Nagoshi, N., Shibata, S., Moritoki, N., Kojima, K., Tsuji, O., Matsumoto, M., Kohyama, J., Nakamura, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46069-z · Cited by 21
Stem Cell Secretome for Spinal Cord Repair: Is It More than Just a Random Baseline Set of Factors?
Pajer, K., Bellák, T., & Nógrádi, A. (2021) · Cells · doi:10.3390/cells10113214 · Cited by 22
Rybniker, J., Nowag, A., Janicki, H., Demant, K., Hartmann, P., & Büning, H. (2012) · Journal of Virology · doi:10.1128/jvi.01708-12 · Cited by 24
Carlon, M. S., Vidović, D., Dooley, J., da Cunha, M. M., Maris, M., Lampi, Y., Toelen, J., Van den Haute, C., Baekelandt, V., Deprest, J., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2013.196 · Cited by 19
“…to the nonintegrating nature of the vector, the lack of appropriate receptors at the apical side of the respiratory epithelium, induction of an immune response against the transgene or vector particle, and the presence of preexisting immunity to the vector (reviewed in Mingozzi and High, 2011).”
BackgroundChai, Z., Zhang, X., Dobbins, A. L., Samulski, R. J., Merricks, E. P., Nichols, T. C., & Li, C. (2022) · Human Gene Therapy · doi:10.1089/hum.2021.083 · Cited by 19
Optimization of CRISPR–Cas system for clinical cancer therapy
Meng, X. L., Wu, T., Lou, Q., Niu, K., Jiang, L., Xiao, Q., Xu, T., & Zhang, L. (2022) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10474 · Cited by 19
“pared to other viral vectors, AAV vectors are widely used for delivery of CRISPR–Cas9 system due to their low immunogenicity, long-lasting transgene expression, mild immune response, high infection efficiency, and general safety.(144,147) However, the low packaging capacity of the AAV vectors (<4.”
BackgroundDevelopment of New Genome Editing Tools for the Treatment of Hyperlipidemia
Preta, G. (2023) · Cells · doi:10.3390/cells12202466 · Cited by 19
“AAV-mediated delivery of the CRISPR-Cas9 system has shown high gene targeting efficacy in vivo and a lower immunogenicity emerging as an alternative delivery method for the CRISPR-Cas9 system to various cell types, tissues, and organs [61,62].”
MethodNovel anti‐tumor mechanism of galanin receptor type 2 in head and neck squamous cell carcinoma cells
Uehara, T., Kanazawa, T., Mizukami, H., Uchibori, R., Tsukahara, T., Urabe, M., Kume, A., Misawa, K., Carey, T. E., Suzuki, M., et al. (2013) · Cancer Science · doi:10.1111/cas.12315 · Cited by 18
Immunological Monitoring to Rationally Guide AAV Gene Therapy
Britten, C. M., Walter, S., & Janetzki, S. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00273 · Cited by 18
Adjei, I. M., Yang, H., Plumton, G., Maldonado-Camargo, L., Dobson, J., Rinaldi, C., Jiang, H., & Sharma, B. (2019) · Drug Delivery and Translational Research · doi:10.1007/s13346-019-00621-6 · Cited by 18
Distinct transduction of muscle tissue in mice after systemic delivery of AAVpo1 vectors
Tulalamba, W., Weinmann, J., Pham, Q. H., Andari, J. E., VandenDriessche, T., Chuah, M., & Grimm, D. (2019) · Gene Therapy · doi:10.1038/s41434-019-0106-3 · Cited by 18
Krotova, K. Y., & Aslanidi, G. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.074 · Cited by 18
Qu, C.-J., Qu, C.-H., Xu, L., Shen, J., Lv, D., Li, Y., Song, H., Li, T.-H., Zheng, J., & Zhang, J.-J. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.11.006 · Cited by 17
Sun, Y.-Y., Wu, D., Yin, N., Yang, L., Chen, X., Li, H.-D., Li, X., Huang, C., Meng, X., Wang, H., et al. (2021) · Clinical Science · doi:10.1042/cs20201363 · Cited by 20
AAV vector-mediated secretion of chondroitinase provides a sensitive tracer for axonal arborisations
Alves, J. N., Muir, E. M., Andrews, M. R., Ward, A., Michelmore, N., Dasgupta, D., Verhaagen, J., Moloney, E. B., Keynes, R. J., Fawcett, J. W., et al. (2014) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2014.02.010 · Cited by 20
Egorova, T. V., Starikova, A. V., & Polikarpova, A. V. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17111492 · Cited by 20
“Numerous studies in mice, dogs, and non-human primates have demonstrated stable transgene expression in target tissues after drug administration without activation of the T-cell immune response [6].”
Xiang, Y. S., & Hao, G. G. (2023) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-023-00518-5 · Cited by 21
Acoustically targeted noninvasive gene therapy in large brain volumes
Nouraein, S., Lee, S., Saenz, V. A., Mundo, H. C. D., Yiu, J., & Szablowski, J. O. (2023) · Gene Therapy · doi:10.1038/s41434-023-00421-1 · Cited by 20
“Recently, multiple clinically approved gene therapeutics and clinical trials [7] have used adeno-associated viral vectors (AAVs), owing to their low pathogenicity, immunogenicity, and durable long-term gene expression [8].”
Rational immunosilencing of a promiscuous T-cell epitope in the capsid of an adeno-associated virus
Bing, S. J., Seirup, M., Hoang, T. T., Najera, S. S., Britten, C. N., Warrington, S., Chu, S.-L., & Mazor, R. (2023) · Nature Biomedical Engineering · doi:10.1038/s41551-023-01129-8 · Cited by 18
“Gene therapy using recombinant adeno-associated virus (AAV) vectors is a promising approach for treating a wide range of inherited and acquired diseases 1 .”
Erickson, S. B., Pham, Q. T., Cao, X., Glicksman, J., Kelemen, R. E., Shahraeini, S. S., Bodkin, S., Kiyam, Z., & Chatterjee, A. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00411 · Cited by 20
Cocaine Hydrolase Gene Therapy for Cocaine Abuse
Brimijoin, S., & Gao, Y. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.11.183 · Cited by 18
Xu, X., Liu, Z., Wang, J., Ling, Q., Xie, H., Guo, H., Wei, X., Zhou, L., & Zheng, S. (2016) · Scientific Reports · doi:10.1038/srep31267 · Cited by 19
“Systemic administration of adeno-associated virus (AAV) vectors results in long-term, robust transgene expression with minimal toxicity and immune responses in several animal models 22 .”
rAAV-Mediated Gene Delivery to Adipose Tissue
Huang, W., Queen, N. J., & Cao, L. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9139-6_23 · Cited by 17
Effects of immunosuppression on circulating adeno-associated virus capsid-specific T cells in humans
Parzych, E. M., Li, H., Yin, X., Liu, Q., Wu, T.-L., Podsakoff, G. M., High, K. A., Levine, M. H., & Ertl, H. C. J. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.246 · Cited by 16
“Recombinant AAVs are used for gene transfer (Mueller and Flotte, 2008; Vandenberghe et al. , 2009; Mingozzi and High, 2011).”
Self-citationShamshad, A., Kang, C., Jenny, L. A., Persad‐Paisley, E. M., & Tsang, S. H. (2023) · Vision Research · doi:10.1016/j.visres.2023.108258 · Cited by 18
Retinal gene therapy: current progress and future prospects
Ku, C. A., & Pennesi, M. E. (2015) · Expert Review of Ophthalmology · doi:10.1586/17469899.2015.1035711 · Cited by 18
“Overcoming obstacles to improve efficacy Since development of the first-generation rAAV2 vector, vast innovations and improvements in viral gene vectors have emerged, largely driven by inefficient transduction of immune-competent organ systems, such as the liver, muscle and heart [37].”
BackgroundPaulk, N. K., Wursthorn, K., Haft, A., Pelz, C., Clarke, G. N., Newell, A. H., Olson, S. B., Harding, C. O., Finegold, M. J., Bateman, R. L., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2012.154 · Cited by 19
Lai, C., Wang, K.-C., Kuo, C., Lee, F.-T., Cheng, T., Chang, B.-I., Yang, Y.-J., Shi, G.-Y., & Wu, H. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.03.024 · Cited by 16
Roadmap for an early gene therapy for cystic fibrosis airway disease
Carlon, M. S., Vidović, D., & Birket, S. E. (2017) · Prenatal Diagnosis · doi:10.1002/pd.5164 · Cited by 17
Kelemen, R. E., Erickson, S. B., & Chatterjee, A. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7574-7_20 · Cited by 17
Enhancing the Therapeutic Potential of Sulfamidase for the Treatment of Mucopolysaccharidosis IIIA
Sorrentino, N. C., Cacace, V., Risi, M. D., Maffia, V., Strollo, S., Tedesco, N., Nusco, E., Romagnoli, N., Ventrella, D., Huang, Y., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.10.009 · Cited by 18
“Molecular Therapy: Methods & Clin This is an open access article under t andmay be generated with variable serotypes allowing efficient delivery of therapeutic genes to different target tissues.(5,6) To date, several therapeutic approaches have been designed and developed based on AAV-mediated gene delivery of SGSH us…”
Shahnaij, M., Iyori, M., Mizukami, H., Kajino, M., Yamagoshi, I., Syafira, I., Yusuf, Y., Fujiwara, K., Yamamoto, D. S., Kato, H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.612910 · Cited by 16
Gene Therapy for Acute Respiratory Distress Syndrome
Liu, J., & Dean, D. A. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2021.786255 · Cited by 19
“However, the application of AAV for clinical trials is still limited because of its small packaging capacity, difficulty producing large quantities, issues with re-dosing, and various immune responses in different organs (Mingozzi and High, 2011; Sondhi et al., 2017; Wang et al., 2019).”
BackgroundAnnual banned‐substance review: analytical approaches in human sports drug testing
Thevis, M., Kuuranne, T., Geyer, H., & Schänzer, W. (2012) · Drug Testing and Analysis · doi:10.1002/dta.415 · Cited by 17
The Application of M 12L 24 Nanocages as Cell-Specific siRNA Delivery Agents in vitro
Bobylev, E. O., Zeng, Y., Weijgertse, K., Koelman, E., Meijer, E. M., de Bruin, B., Kros, A., & Reek, J. N. H. (2022) · Chem · doi:10.1016/j.chempr.2023.03.018 · Cited by 16
Wang, D. B., Gitcho, M. A., Kraemer, B. C., & Klein, R. L. (2011) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2011.07803.x · Cited by 21
“Although AAV vector strategies are promising for gene therapy as well as studying disease mechanisms, gene therapy clinical trials for hemophilia, for example, have had difficulty in translation, despite clear-cut efficacy in animal models (Mingozzi & High, 2011).”
BackgroundNomikou, N., & McHale, A. P. (2012) · International Journal of Hyperthermia · doi:10.3109/02656736.2012.659235 · Cited by 17
“Over the past decade the method of choice for achieving efficient gene transfer in vivo for therapeutic purposes has involved the use of viral vectors, primarily because these have the ability to transfer nucleic acid into cells in an extremely efficient manner [1].”
BackgroundMethodTAR Cloning: Perspectives for Functional Genomics, Biomedicine, and Biotechnology
Kouprina, N., & Larionov, V. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.05.006 · Cited by 19
Pearce, H. A., Qian, H., Connell, T. U., Huang, D., Gottstein, C., Donnelly, P. S., Peter, K., Gregorevic, P., & Hagemeyer, C. E. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.07.003 · Cited by 16
“Molecular Therapy: Methods & Clinic This is an open access article under the CC BY-NCfeatures, in that they are associated with low inflammation and pathogenicity and offer long-term expression.(3) While all available vectors show low endothelial transduction levels, rAAV transduction is particularly low, with 3% of c…”
BackgroundKim, M., Jo, S., Park, J. M., Kim, T. H., Im, S., & Ahn, Y. (2012) · Diabetologia · doi:10.1007/s00125-012-2807-7 · Cited by 16
“To this end, we adopted AAV serotype 2 as a gene delivery vehicle because of its excellent safety and the greater duration of its transgene expression capability [25].”
MethodGene therapy: therapeutic applications and relevance to pathology
Both, G. W., Alexander, I. E., Fletcher, S., Nicolson, T. J., Rasko, J. E. J., Wilton, S. D., & Symonds, G. P. (2011) · Pathology · doi:10.1097/pat.0b013e32834b1dad · Cited by 17
“AAV-8 vector administered intravenously have shown promise.(120) Advances in biotechnology manufacturing have improved the yields and purity of clinical grade vector”
BackgroundStructure–activity correlation in transfection promoted by pyridinium cationic lipids
Parvizi, P., Mendez-Campos, J., Raju, L., Khalique, N. A., Jubeli, E., Larsen, H. B., Nicholson, D., Pungente, M. D., & Fyles, T. M. (2016) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob00041j · Cited by 16
Gene therapeutic approaches to inhibit hepatitis B virus replication
Gebbing, M., Bergmann, T., Schulz, E., & Ehrhardt, A. (2014) · World Journal of Hepatology · doi:10.4254/wjh.v7.i2.150 · Cited by 17
Siu, J. J., Queen, N. J., Huang, W., Yin, F., Liu, X., Wang, C., McTigue, D. M., & Cao, L. (2017) · Gene Therapy · doi:10.1038/gt.2017.27 · Cited by 18
“rAAV vectors have become the preferred in vivo gene delivery system because of their characteristics including broad tropism of both dividing and postmitotic tissues, high efficiency of gene transfer, long-lasting transgene expression, low immunogenicity, and minimal toxicity (2).”
Tchedre, K. T., Batabyal, S., Galicia, M., Narcisse, D., Mustafi, S. M., Ayyagari, A. L., Chavala, S. H., & Mohanty, S. K. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16823 · Cited by 17
Emerging uses for pediatric hematopoietic stem cells
Domen, J., Gandy, K. L., & Dalal, J. D. (2012) · Pediatric Research · doi:10.1038/pr.2011.55 · Cited by 15
Sharma, A., Mathew, M. E., Sriganesh, V., & Reiss, U. M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010822.pub3 · Cited by 16
Barbon, E., Pignani, S., Branchini, A., Bernardi, F., Pinotti, M., & Bovolenta, M. (2016) · Scientific Reports · doi:10.1038/srep28304 · Cited by 15
Alliegro, M., Ferla, R., Nusco, E., Leonibus, C. D., Settembre, C., & Auricchio, A. (2016) · Molecular Therapy · doi:10.1038/mt.2016.181 · Cited by 15
“In this study we show in a mouse model the therapeutic efficacy of a novel combinatorial gene therapy/ERT approach for MPS VI, and potentially other LSDs.”
InfluentialProgress in HIV-1 antibody research using humanized mice
Gruell, H., & Klein, F. (2017) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000368 · Cited by 15
Eş, İ., Ok, M. T., Puentes-Martinez, X. E., Toledo, M. A. S., Favaro, M. T. D. P., Cavalcanti, L. P., Cassago, A., Portugal, R. V., Azzoni, A. R., & de la Torre, L. G. (2018) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2018.06.073 · Cited by 15
Prakoso, D., Tate, M., Blasio, M. J. D., & Ritchie, R. H. (2021) · Clinical Science · doi:10.1042/cs20210052 · Cited by 17
Gene Therapy for Hemophilia: The Clot Thickens
High, K. A. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.2541 · Cited by 18
“Mingozzi & High.”
Self-citationHambach, J., Mann, A. M., Bannas, P., & Koch‐Nolte, F. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1005800 · Cited by 14
Targeting of CRISPR-Cas12a crRNAs into human mitochondria
Nikitchina, N., Ulashchik, E. A., Shmanai, V. V., Heckel, A., Tarassov, I., Mazunin, I., & Entelis, N. (2023) · Biochimie · doi:10.1016/j.biochi.2023.09.006 · Cited by 16
Promising tools for future drug discovery and development in antiarrhythmic therapy
Mondéjar‐Parreño, G., Sánchez-Pérez, P., Cruz, F. M., & Jalife, J. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.124.001297 · Cited by 17
Zhu, F., Chen, T., Zhang, Y., Sun, H., Cao, H., Lu, J., Zhao, L., & Li, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142349 · Cited by 14
“It has been identified as safe in human clinical trials and effective in the treatment of rare inherited diseases [26].”
BackgroundA Simple, Two-Step, Small-Scale Purification of Recombinant Adeno-Associated Viruses
Chen, S., Papaneri, A. B., Walker, M., Scappini, E., Keys, R. D., & Martin, N. P. (2020) · Journal of Virological Methods · doi:10.1016/j.jviromet.2020.113863 · Cited by 15
Transduction of Surface and Basal Cells in Rhesus Macaque Lung Following Repeat Dosing with AAV1CFTR
Guggino, W. B., Yanda, M. K., Cebotaru, C. V., & Cebotaru, L. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.207 · Cited by 17
Gene therapy for a murine model of eosinophilic esophagitis
Camilleri, A. E., Nag, S., Russo, A. R., Stiles, K. M., Crystal, R. G., & Pagovich, O. E. (2021) · Allergy · doi:10.1111/all.14822 · Cited by 14
Ran, G., Feng, X.-L., Xie, Y., Zheng, Q., Guo, P., Yang, M., Feng, Y., Ling, C., Zhu, L., & Chen, Z. (2021) · Journal of Chinese Integrative Medicine · doi:10.1016/j.joim.2021.09.004 · Cited by 14
Successful treatment of severe MSUD in Bckdhb −/− mice with neonatal AAV gene therapy
Pontoizeau, C., Gaborit, C., Tual, N., Sola, M. S., Rotaru, I., Benoist, M., Colella, P., Lamazière, A., Brassier, A., Arnoux, J., et al. (2023) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12604 · Cited by 14
“Adeno-associated virus (AAV) vectors are suitable tools to perform gene transfer to the liver or other organs 11 and have been used in the field of inborn errors of metabolism to treat animal models of urea cycle disorders, 12 – 16 organic acidemia, 17,18 phenylketonuria 19 and others, and are used…”
MethodSelf-citationApplying Gene Silencing Technology to Contraception
Dissen, G. A., Lomniczi, A., Boudreau, R. L., Chen, Y., Davidson, B. L., & Ojeda, S. (2012) · Reproduction in Domestic Animals · doi:10.1111/rda.12016 · Cited by 15
Perspective on innovative therapies for globoid cell leukodystrophy
Ricca, A., & Gritti, A. (2016) · Journal of Neuroscience Research · doi:10.1002/jnr.23752 · Cited by 16
Structure of the AAVhu.37 capsid by cryoelectron microscopy
Kaelber, J. T., Yost, S. A., Webber, K., Firlar, E., Liu, Y., Danos, O., & Mercer, A. C. (2020) · Acta Crystallographica Section F Structural Biology Communications · doi:10.1107/s2053230x20000308 · Cited by 15
“…dividing and quiescent cells makes them promising candidates for the delivery of many clinically relevant cargoes; however, challenges remain regarding capsid engineering, including tissue-specific transduction, avoidance of the innate immune response and manufacturability (Mingozzi & High, 2011).”
BackgroundScala, M. D., Gil-Fariña, I., Olagüe, C., Vales, Á., Sobrevals, L., Fortes, P., Corbacho, D., & González‐Aseguinolaza, G. (2016) · Oncotarget · doi:10.18632/oncotarget.10264 · Cited by 17
“Among the viral-based vectors employed in gene therapy, recombinant adeno-associated virus (rAAV) is one of the most promising since it has many attractive features including demonstrated safety, efficacy and long term expression in humans [24-26].”
BackgroundCurrent trends in gene therapy to treat inherited disorders of the brain
Matuszek, Ż., Brown, B. L., Yrigollen, C. M., Keiser, M. S., & Davidson, B. L. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.057 · Cited by 14
Beraza-Millor, M., Rodríguez-Castejón, J., del Pozo‐Rodríguez, A., Rodríguez‐Gascón, A., & Solinís, M. Á. (2024) · BioDrugs · doi:10.1007/s40259-024-00674-1 · Cited by 16
“The AAV packaging capacity of 4.7 kb limits carrying large genes, such as CRISPR/Cas9 machinery [113].”
InfluentialOlarewaju, O., Held, F., Curtis, P., Kenny, C. H., Maier, U., Panavas, T., & du Plessis, F. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101378 · Cited by 14
Li, Y., Zhong, Y., Cheng, Q., Wang, Y., Fan, Y., Yang, C., Ma, Z., Li, Y., & Li, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00717 · Cited by 15
“The adeno-associated virus (AAV, serotype 9, a gift from GeneChem, Shanghai, China), which has higher infection efficiency and induces long-lasting expression, was used in packaging recombinant AAV (Mingozzi and High, 2011).”
MethodDisease modeling and stem cell immunoengineering in regenerative medicine using CRISPR/Cas9 systems
Antao, A. M., Karapurkar, J. K., Lee, D. R., Kim, K.-S., & Ramakrishna, S. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.11.026 · Cited by 14
Chen, D., Wu, C., Wei, S., Guo, Y., Wu, M., Zhou, S., Fu, F., Tang, W., Xue, L., Zhang, J., et al. (2023) · Molecular Human Reproduction · doi:10.1093/molehr/gaad010 · Cited by 16
Kato, M., Ishikawa, S., Shen, Q., Du, Z., Katashima, T., Naito, M., Numahata, T., Okazaki, M., Sakai, T., & Kurita, M. (2023) · Communications Biology · doi:10.1038/s42003-023-04851-w · Cited by 14
Naumer, M., Popa-Wagner, R., & Kleinschmidt, J. A. (2012) · Journal of General Virology · doi:10.1099/vir.0.044735-0 · Cited by 14
Brimijoin, S. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711799219398 · Cited by 13
“At present there appear to be two viable candidates for vector of choice in regard to cocaine hydrolase gene transfer: helper dependent adenovirus (hdAD), serotype 5 [76–78], and AAV serotype 2/8 [79].”
BackgroundShi, Y., Falahati, R., Zhang, J., Flebbe-Rehwaldt, L., & Gaensler, K. M. L. (2013) · Gene Therapy · doi:10.1038/gt.2013.22 · Cited by 15
Vásquez, M., Cervantes, V. P., Aranda, F., Ardaiz, N., Gomar, C., & Berraondo, P. (2016) · Oncotarget · doi:10.18632/oncotarget.14127 · Cited by 13
“Several clinical trials have demonstrated the safety, efficiency, and efficacy of these vectors [8].”
BackgroundGene therapy in monogenic congenital myopathies
Guan, X., Goddard, M. A., Mack, D. L., & Childers, M. K. (2015) · Methods · doi:10.1016/j.ymeth.2015.10.004 · Cited by 15
Development and Challenges of Nanovectors in Gene Therapy
Liu, Y., Rohrs, J. A., & Wang, P. (2014) · Nano LIFE · doi:10.1142/s1793984414410074 · Cited by 13
Yue, Y., Yin, W., Wei, W., Ren, J., Tan, L., Wang, J., Liu, J., Lu, Q., Ding, H., Yang, Q., et al. (2020) · Infection and Immunity · doi:10.1128/iai.00498-20 · Cited by 12
“It has been found to be safe and nonpathogenic in both animal and human hosts and causes only mild immune responses (23).”
Portal Vein Delivery of Viral Vectors for Gene Therapy for Hemophilia
Sherman, A., Schlachterman, A., Cooper, M., Merricks, E. P., Raymer, R. A., Bellinger, D. A., Herzog, R. W., & Nichols, T. C. (2014) · Methods in molecular biology · doi:10.1007/978-1-62703-761-7_27 · Cited by 13
“AAV vectors have a single-stranded or self-complementary (sc) DNA genome and are devoid of viral coding sequences [15].”
BackgroundMroske, C., Rivera, H., Ul-Hasan, T., Chatterjee, S., & Wong, K. K. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2011.231 · Cited by 13
“…AAV protocols approved by the Recombinant DNA Advisory Committee (National Institutes of Health, Bethesda, MD) and U.S. Food and Drug Administration (Silver Spring, MD) for the treatment of diseases ranging from cystic fibrosis to rheumatoid arthritis (Daya and Berns, 2008; Mingozzi and High, 2011).”
RETRACTED ARTICLE: Liposome-lentivirus for miRNA therapy with molecular mechanism study
Sun, F., Chen, H., Dai, X., Hou, Y., Li, J., Zhang, Y., Huang, L., Guo, B., & Yang, D. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02534-0 · Cited by 12
“Interestingly, in comparison to the non-viral meth-ods, viruses are highly-evolved, natural delivery agents used as the genetic materials [17].”
BackgroundRetractedCompact RNA editors with natural miniature Cas13j nucleases
Li, G., Cheng, Y., Yu, J., Zhu, Y., Ma, H., Zhou, Y., Pu, Z., Zhu, G., Yuan, Y., Zhang, Z., et al. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01729-8 · Cited by 13
Neuroprotection by rAAV-mediated gene transfer of bone morphogenic protein 7
Heinonen, A.-M., Rahman, M., Dogbevia, G., Sonntag, H., Wölfl, S., Sprengel, R., & Schwaninger, M. (2014) · BMC Neuroscience · doi:10.1186/1471-2202-15-38 · Cited by 13
Chen, Q., Qi, R., Chen, X., Yang, X., Huang, X., Xiao, H., Wang, X., & Dong, W. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b06782 · Cited by 11
Vil, L., Roca, C., Elias, I., Casellas, A., Lage, R., Franckhauser, S., & Bosch, F. (2016) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2016.72 · Cited by 12
Advanced nanotherapies to promote neuroregeneration in the injured newborn brain
Arteaga, O., Mikrogeorgiou, A., Kannan, S., & Ferriero, D. M. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.10.005 · Cited by 12
Wang, Y., Lu, J., Li, Y., Zhong, Y., Yang, C.-F., Zhang, Y., Huang, L.-H., Huang, S.-M., Li, Q.-R., Wu, D., et al. (2021) · Bioengineered · doi:10.1080/21655979.2021.2003677 · Cited by 11
“Adeno-associated CCTED virus (AAV, serotype 9, a gift from Gene Chem, Shanghai, China) showed higher infection efficiency and induced persistent expression, and was used to package recombinant AAV [20].”
MethodLu, J., Zhang, Y., Wang, Y., Li, Y., Wang, R., Zhong, Y.-J., Chen, L., Song, M.-W., Li, L., Li, Y., et al. (2022) · Bioengineered · doi:10.1080/21655979.2022.2060586 · Cited by 16
“Adeno-associated virus (AAV, serotype 9) was used to package recombinant AAV on account of high infection efficiency and stability [27].”
MethodXue, Y., Zhang, J., Ke, J., Zeng, L., Cheng, K., Han, X., Chen, F., & Chen, F. (2022) · Inflammation Research · doi:10.1007/s00011-022-01644-5 · Cited by 12
“AAV vectors are typically regarded as safe and effective in vivo gene delivery tools for long-term transduction, which do not encode viral proteins and cannot induce immune response [28].”
BackgroundWinbanks, C. E., Beyer, C., Qian, H., & Gregorevic, P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0051627 · Cited by 11
“To this end, rAAV vectors have shown promise as prospective interventions for understanding and treating a variety of conditions affecting the neuromuscular, cardiac, respiratory, hepatic, circulatory and sensory systems [2].”
BackgroundYu, Z., Zhou, S., Luo, N., Ho, C. Y., Chen, M., & Chen, H. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.11.009 · Cited by 14
Metadata
- Authors
- Mingozzi, F., & High, K. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- Corresponding author
- High, Katherine A.
- Venue
- Nature Reviews Genetics
- Published
- 2011-04-18
- Volume
- 12
- Issue
- 5
- Pages
- 341-355
- ISSN
- 1471-0056 (ISSN-L)
- 1471-0064
- OpenAlex
- W2012894204
- Cited by
- 893
- References
- 177
- Citations by year
- 2026: 13 · 2025: 30 · 2024: 51 · 2023: 39 · 2022: 43 · 2021: 53 · 2020: 66 · 2019: 62 · 2018: 66 · 2017: 80 · 2016: 70 · 2015: 82 · 2014: 74 · 2013: 73 · 2012: 65
- FWCI
- 7.96
- Type
- journal article
- Language
- en
- Update notices
- erratum (2011-05-24)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- National Heart, Lung, and Blood Institute (P01HL064190, HL64190, HL078810, P01HL078810)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Keywords
- adeno-associated virus vectors, gene therapy, in vivo gene delivery, genetic disorders, gene replacement, inherited retinal disease, hemophilia B
- MeSH terms
- Dependovirus, Animals, Hemophilia B, Clinical Trials as Topic, Dogs, Genetic Vectors, Humans, Male, Retinal Diseases, Genetic Therapy, Gene Transfer Techniques, Genetic Diseases, Inborn, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.